Patient disposition. † indicates that a patient could have multiple reasons for screening failure. ‡, The primary efficacy end point was assessed using the full analysis set. §, Five patients from Egypt and 1 patient from Italy. ‖AEs that led to discontinuation were abdominal pain (2), arthritis (1), drug rash with eosinophilia and systemic symptoms (1), and pruritus (1). ¶, Four patients had mT2* <6 ms at baseline, and 1 patient had mT2* of 6.1 ms at study entry. ††, Last available value within month 12 window included in efficacy analysis, with exception of month 12 mT2* where LOCF was used. ‡‡, Two patients were measured within the month 24 window and were included in efficacy analyses, but failed to complete the full 24 months.